Testing BR1400 drugs for essential hypertension in adults
Tests BR1400-1, BR1400-2, BR1400-3, BR1400-4 and BR1400-5 in adults with essential hypertension.
Plain-language title generated from the registry record
Registry title: A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
Key facts
- Where
- Soeul, South KoreaSee the site
- Phase
- Phase 2
Where in South Korea
- Hanyang University HospitalSoeul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boryung Pharmaceutical Co., Ltd
- Trial code
- NCT07373613
- Record updated
- 28 January 2026
- Original description
The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.Read full original descriptionShow less
A Randomized, Multi-center, Double-Blind, Controlled, Parallel Design, Phase II Study to Evaluate the Efficacy and Safety Administration by Doses of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.
Inclusion: <Screening Visit (V1)>; Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the screening (Visit 1) meets the following criteria:; For patients not currently receiving antihypertensive therapy: 140 mmHg ≤ MSSBP < 180 mmHg; For patients receiving antihypertensive therapy : 130 mmHg ≤ MSSBP < 180 mmHg; For patients receiving antihypertensive therapy at the screening (Visit 1), those for whom the investigator determines that it is medically appropriate to temporarily discontinue their current antihypertensive treatment during the study; <Baseline Visit (V2)>; Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the baseline (Visit 2) prior to randomization meets the following criteria:; For patients without cardiovascular disease: 140 mmHg ≤ MSSBP < 180 mmHg; For patients with cardiovascular disease, diabetes with cardiovascular disease, albuminuria, or diabetes with chronic kidney disease (CKD): 130 mmHg ≤ MSSBP < 180 mmHg.
Exclusion: Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.); Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1) and baseline(V2); Patients with shock; Patients with orthostatic hypotension accompanied by symptoms.